ASX Announcement

IMUGENE COMMENCES COHORT 2 DOSING IN PHASE I CLINICAL TRIAL OF NEW CHECKPOINT IMMUNOTHERAPY PD1-VAXX

SYDNEY, Australia, 12 February 2021: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced it has dosed the first patient in cohort 2 in the Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx.

The first patient in the mid-dose (50µg) cohort 2 was dosed at the Hackensack University Medical Center in New Jersey, USA.

The first-in-human, Phase 1, multi-center, dose escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer. Medical investigators will test three different doses of PD1-Vaxx. The primary aim of the Phase 1 trial is to determine safety and an optimal biological dose as a monotherapy (mOBD). Efficacy, tolerability and immune response will also be measured.

Imugene MD & CEO Leslie Chong said "The start of our FDA IND approved clinical trial formally in the USA, the largest pharmaceutical market globally, is a significant milestone for Imugene."

Imugene's PD1-Vaxx is a B-cell cancer immunotherapy designed to treat tumors such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.

Full study details can also be found on clinical trials.gov under study ID: NCT04432207.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer